HDAC9 and melanoma: To examine the combinatorial effect of HDAC and mutant BRAF inhibitors on melanoma cells in vivo, we transplanted subcutaneously MM200 and Sk-Mel-28 cells, which were resistant to PLX4720 or SAHA alone in vitro (Figure 1a),36 into nu/nu mice.